Novel cancer therapies and their association with diabetes.

Journal Article (Journal Article;Review)

Over the last decade, there has been a shift in the focus of cancer therapy from conventional cytotoxic drugs to therapies more specifically directed to cancer cells. These novel therapies include immunotherapy, targeted therapy and precision medicine, each developed in great part with a goal of limiting collateral destruction of normal tissues, while enhancing tumor destruction. Although this approach is sound in theory, even new, specific therapies have some undesirable, 'off target effects', in great part due to molecular pathways shared by neoplastic and normal cells. One such undesirable effect is hyperglycemia, which results from either the loss of immune tolerance and autoimmune destruction of pancreatic β-cells or dysregulation of the insulin signaling pathway resulting in insulin resistance. These distinct pathogenic mechanisms lead to clinical presentations similar to type 1 (T1DM) and type 2 (T2DM) diabetes mellitus. Both types of diabetes have been reported in patients across clinical trials, and data on the mechanism(s) for developing hyperglycemia, prevalence, prognosis and effect on cancer mortality is still emerging. With the rapidly expanding list of clinical indications for new cancer therapies, it is essential to understand the impact of their adverse effects. In this review, we focus on hyperglycemia and diabetes related to cancer therapies, describe what is known about mechanism(s) leading to dysregulated glucose metabolism and provide a guide to management of complex oncology patients with a new diagnosis of diabetes.

Full Text

Duke Authors

Cited Authors

  • Shariff, AI; Syed, S; Shelby, RA; Force, J; Clarke, JM; D'Alessio, D; Corsino, L

Published Date

  • February 1, 2019

Published In

Volume / Issue

  • 62 / 2

Start / End Page

  • R187 - R199

PubMed ID

  • 30532995

Electronic International Standard Serial Number (EISSN)

  • 1479-6813

Digital Object Identifier (DOI)

  • 10.1530/JME-18-0002


  • eng

Conference Location

  • England